Novo Nordisk Revenue and Competitors

Princeton Meadows, NJ USA

Location

N/A

Total Funding

Industry

Employee Data

  • Novo Nordisk has 139 Employees.(i)
  • Novo Nordisk grew their employee count by 72% last year.

Novo Nordisk's People

NameTitleEmail/Phone
1
VP and General ManagerReveal Email/Phone
2
Head Finance, Procurement and ComplianceReveal Email/Phone
3
Marketing DirectorReveal Email/Phone
4
National Sales DirectorReveal Email/Phone
5
Export Sales ManagerReveal Email/Phone
6
Diabetes Care Specialist II at Novo Nordisk, IncReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$16.1M801%N/AN/A
#2
$32820M834497%N/A$182.4B
#3
$69340M1073104%N/A$308.4B
Add Company

What Is Novo Nordisk?

Located in Princeton, New Jersey, headquarters for our North American business, Novo Nordisk Pharmaceuticals, Inc. has more than 1,000 employees nationwide handling sales, marketing and managed care activities, along with medical, regulatory, legal, strategic business operations and human resources responsibilities. We're the United States affiliate of Novo Nordisk A/S, Copenhagen, Denmark a world leader in diabetes care and other pharmaceutical products. And at our manufacturing facility in Clayton, North Carolina, we have more than 350 employees supplying insulin to the United States diabetes market and throughout the world.

keywords:N/A

N/A

Total Funding

139

Number of Employees

N/A

Revenue (est)

72%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Novo Nordisk News

2022-04-19 - Novo Nordisk: Firing On All Cylinders, Which Is Reflected By The Share Price

Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. · And due to anti-obesity...

2022-04-19 - Novo Nordisk: Firing On All Cylinders, Which Is Reflected By The Share Price

Novo Nordisk reported strong growth in fiscal 2021 with revenue and earnings per share growing in the double digits. · And due to anti-obesity...

2022-04-17 - Novo Nordisk: Growing Obesity Epidemic Will Generate Strong Demand

Novo Nordisk (NYSE:NVO), the world's leading producer of diabetes therapies that owns nearly 50% of the insulin market, is constantly trying...

2022-04-17 - Novo Nordisk: Growing Obesity Epidemic Will Generate Strong Demand

Novo Nordisk (NYSE:NVO), the world's leading producer of diabetes therapies that owns nearly 50% of the insulin market, is constantly trying...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$120.2M583N/AN/A
#2
$842.2M22284%N/A
#3
$421.4M31174%N/A
#4
N/A7813-23%N/A
#5
$134600M641785%N/A